M2 Presswire - Pfizers Atorvastatin + Torcetrapib Combination is Expected to Have a Major Impact on the Dyslipidemia Market and is Expected to Compete with Both Atorvastatin…
M2 PRESSWIRE-17 February 2006-Research and Markets: Pfizers Atorvastatin Torcetrapib Combination is Expected to Have a Major Impact on the Dyslipidemia Market and is Expected to Compete with Both Atorvastatin and Vytorin(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:17022006 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c33178) has announced the addition of Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth to their offering The antidyslipidemics market is driven by the statins, which account for 87 of it.
Related Results
CORRECTIONS/CLARIFICATIONS
WALL STREET CHOICE: BEATING GUIDANCE WITH NEW DRUGS AND LOWER COSTS
Merck and Schering-Plough's statin combo hits pharmacies
New Study Showed VYTORIN Significantly More Effective than Crestor…
Vytorin study raises questions about Cholesterol’s Import
However, as many …
Read the rest of this article with a Free Trial at HighBeam Research.
